| 000 | 01517nam a22003257c 4500 | ||
|---|---|---|---|
| 001 | 00006118 | ||
| 003 | ES-MaONT | ||
| 005 | 20231116104403.0 | ||
| 008 | 200902s2020 d||| t||| 00| 0 eng d | ||
| 040 | _aES-MaONT | ||
| 245 | 1 | 0 |
_aNo going back _b: Pharma companies’ route to a digitized go-to-market model _c/ [authors, Thomas Solbach ... et al.] |
| 260 |
_a[S.l.]: _bPwC, _c2020 |
||
| 300 |
_a13 p.: _bgráf. ; _c1 documento PDF |
||
| 336 |
_atexto (visual) _2isbdcontent |
||
| 337 |
_aelectrónico _2isbdmedia |
||
| 338 |
_arecurso en línea _2rdacarrier |
||
| 500 | _aEn la cubierta: "As COVID-19 digitizes healthcare, we suggest five steps for pharma companies to transform their market engagement | ||
| 520 | _aDigital technologies and interactions are transforming healthcare at an accelerating pace. Until recently, most touchpoints between physicians and pharma companies depended on face-to-face interaction, which often required field forces to drive hundreds of time-consuming kilometers for meetings with doctors. | ||
| 650 | 7 |
_aSanidad digital _92065 |
|
| 653 | _aCOVID-19 | ||
| 653 | _adigitized | ||
| 653 | _ahealthcare | ||
| 653 | _atechnological advances | ||
| 653 | _aTransformación digital | ||
| 700 | 1 |
_aSolbach, Thomas _94612 |
|
| 710 | 2 |
_aPricewaterhouseCoopers _92421 |
|
| 856 | 4 |
_uhttps://www.strategyand.pwc.com/de/en/industries/health/pharmas-route-to-digitization/pharmas-route-to-digitization.pdf _x0 _yAcceso al documento _qpdf |
|
| 942 |
_cINF _2z |
||
| 999 |
_c6118 _d6118 |
||